Kyowa Kirin Past Earnings Performance
Past criteria checks 5/6
Kyowa Kirin has been growing earnings at an average annual rate of 8.6%, while the Pharmaceuticals industry saw earnings growing at 4.3% annually. Revenues have been growing at an average rate of 5.8% per year. Kyowa Kirin's return on equity is 9.7%, and it has net margins of 18.4%.
Key information
8.6%
Earnings growth rate
8.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 3.4% |
| Revenue growth rate | 5.8% |
| Return on equity | 9.7% |
| Net Margin | 18.4% |
| Next Earnings Update | 07 May 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Kyowa Kirin makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 442,233 | 81,188 | 163,078 | 72,106 |
| 30 Sep 23 | 420,649 | 57,915 | 158,138 | 69,927 |
| 30 Jun 23 | 412,309 | 40,202 | 162,077 | 68,639 |
| 31 Mar 23 | 404,155 | 50,295 | 161,796 | 65,906 |
| 31 Dec 22 | 398,371 | 53,573 | 166,185 | 62,896 |
| 30 Sep 22 | 382,052 | 68,651 | 148,265 | 61,591 |
| 30 Jun 22 | 372,496 | 62,292 | 144,307 | 59,093 |
| 31 Mar 22 | 358,882 | 55,464 | 139,539 | 59,095 |
| 31 Dec 21 | 352,246 | 52,347 | 135,105 | 57,679 |
| 30 Sep 21 | 338,317 | 42,446 | 132,495 | 55,518 |
| 30 Jun 21 | 325,554 | 44,301 | 125,537 | 54,739 |
| 31 Mar 21 | 322,174 | 46,106 | 118,474 | 52,705 |
| 31 Dec 20 | 318,352 | 47,027 | 116,525 | 52,312 |
| 30 Sep 20 | 314,367 | 48,255 | 110,498 | 52,674 |
| 30 Jun 20 | 312,223 | 46,819 | 109,172 | 52,702 |
| 31 Mar 20 | 307,278 | 42,212 | 109,275 | 53,393 |
| 31 Dec 19 | 305,820 | 37,674 | 106,245 | 53,511 |
| 30 Sep 19 | 374,267 | 38,519 | 121,871 | 54,203 |
| 30 Jun 19 | 325,827 | 38,796 | 107,909 | 50,395 |
| 31 Mar 19 | 337,645 | 41,713 | 108,972 | 49,594 |
| 31 Dec 18 | 346,531 | 54,414 | 110,283 | 48,591 |
| 30 Sep 18 | 292,662 | 65,953 | 95,512 | 45,242 |
| 30 Jun 18 | 349,815 | 63,500 | 108,093 | 47,611 |
| 31 Mar 18 | 347,166 | 56,420 | 106,321 | 48,301 |
| 31 Dec 17 | 353,380 | 42,899 | 104,608 | 49,155 |
| 30 Sep 17 | 343,697 | 21,949 | 101,407 | 51,146 |
| 30 Jun 17 | 344,648 | 21,576 | 100,090 | 51,138 |
| 31 Mar 17 | 345,485 | 19,754 | 100,666 | 51,855 |
| 31 Dec 16 | 343,019 | 18,669 | 100,621 | 53,792 |
| 30 Sep 16 | 349,134 | 20,199 | 103,038 | 54,156 |
| 30 Jun 16 | 359,535 | 31,014 | 104,852 | 54,670 |
| 31 Mar 16 | 363,187 | 32,566 | 104,818 | 53,096 |
| 31 Dec 15 | 364,316 | 29,774 | 105,702 | 51,518 |
| 30 Sep 15 | 367,453 | 29,906 | 104,174 | 51,343 |
| 30 Jun 15 | 350,384 | 16,236 | 103,163 | 49,892 |
| 31 Mar 15 | 336,965 | 14,173 | 101,054 | 49,442 |
| 31 Dec 14 | 333,446 | 15,898 | 99,396 | 47,667 |
| 30 Sep 14 | 327,444 | 18,791 | 100,050 | 45,405 |
| 30 Jun 14 | 332,803 | 21,585 | 98,603 | 44,541 |
| 31 Mar 14 | 340,090 | 26,010 | 85,674 | 53,986 |
| 31 Dec 13 | 340,611 | 30,078 | 98,037 | 43,633 |
| 30 Sep 13 | 340,570 | 32,082 | 97,370 | 41,873 |
| 30 Jun 13 | 336,575 | 30,354 | 100,735 | 43,642 |
Quality Earnings: 4151 has high quality earnings.
Growing Profit Margin: 4151's current net profit margins (18.4%) are higher than last year (13.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4151's earnings have grown by 8.6% per year over the past 5 years.
Accelerating Growth: 4151's earnings growth over the past year (51.5%) exceeds its 5-year average (8.6% per year).
Earnings vs Industry: 4151 earnings growth over the past year (51.5%) exceeded the Pharmaceuticals industry 0.6%.
Return on Equity
High ROE: 4151's Return on Equity (9.7%) is considered low.